ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Jun 15, 2018
Visa!
Image shown: The performance of Visa since it was added to the Best Ideas Newsletter portfolio. The Best Ideas Newsletter portfolio has a habit of identifying outperforming stock ideas.
Jun 15, 2018
Dividend Increases/Decreases for the Week Ending June 15
Let's take a look at companies that raised/lowered their dividend this week.
Jun 13, 2018
Private Equity Likely Interested in GameStop As Netflix Shocks Gaming Industry
Netflix may have taken the initial steps to enter the video-gaming market. Even as the digital streaming of games may have already signaled the death knell of GameStop’s lucrative physical used-game business, that Netflix may be moving into video games may further truncate not only GameStop’s longevity, but also have ramifications across the entire video-gaming landscape. Private equity may be interested in GameStop, nonetheless.
Jun 13, 2018
The Promise of CAR-T Therapy
Image Source: Gilead. The medical field, particularly the biotech industry, is quite innovative, and advances in medicine can help a specific target population with the ultimate gift--the gift of a better life. We’re excited by the stunning advances in the CAR-T field for the treatment for various forms of cancer that have, in the past, come with an often-bleak prognosis. We expect a shift in the advances in immune-oncology as the CAR-T revolution is in its early stages.
Jun 12, 2018
Verint Trading Near 52-Week Highs
Image Source: Verint. Simulated Best Ideas Newsletter portfolio idea Verint turned in a solid fiscal first quarter report June 7 as ongoing demand strength drove its top line higher. The company's transition to a more software-focused business model is expected to continue expanding margins. Verint is a unique play on cybersecurity.
Jun 11, 2018
Merck’s Dominance in Immuno-Oncology Expands Once Again
Image Source: Merck. Merck simply blew away the competition--the results are simply incredible. Keytruda is a gamechanger, and we think it will become the top-selling pharmaceutical once the patent lapses on Humira.
Jun 8, 2018
Dividend Increases/Decreases for the Week Ending June 8
Let's take a look at companies that raised/lowered their dividend this week.
Jun 7, 2018
Microsoft Wins GitHub Over Alphabet
Image Source: Microsoft deal presentation. Microsoft has agreed to acquire GitHub for $7.5 billion. Competing bids may have driven the price tag higher, but Microsoft’s financial flexibility remains top-notch.
Jun 5, 2018
Fishing Trends Benefiting Many Sporting Goods Retailers
Johnson Outdoors is benefiting greatly from fishing-related sales, and such a tailwind may be helping other sporting goods retailers in the group. New store openings continue to drive Dick’s Sporting Goods’ top-line higher, but the company’s materially increased profit guidance for fiscal 2018 stole the show in its fiscal first quarter report.
Jun 5, 2018
Evercore Partners (EVR) - Fair Value Estimate: ~$130 Per Share; Dividend Cushion Ratio: 4.9
Image shown: The share-price performance of Evercore Partners since July 2017.Evercore’s financial performance in recent years has been impressive as its net revenues have grown at an 18% CAGR since 2011, adjusted earnings per share have advanced at a 22% CAGR, and operating margins have expanded by more than 6 percentage points. The company is working to sustain operating margins of 25%+ in solid M&A markets, which it anticipates will continue in the near term. We currently value shares at ~$130 each. Evercore currently registers an impressive Dividend Cushion ratio of 4.9. Shares yield ~1.8%.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.